Skip to main content
Journal of Ophthalmic Inflammation and Infection

Table 4 Antibiotic susceptibilities among published reports

From: Endophthalmitis caused by Burkholderia cepacia complex (BCC): clinical characteristics, antibiotic susceptibilities, and treatment outcomes

  

Amino-glycosides

Fluoroquinolones

  

Cephalosporins

Study

Patients

Gentamycin

Amikacin

Tobramycin

Ciprofloxacin

Levofloxacin

Ofloxacin

Gatifloxacin

Moxifloxacin

Minocycline

Chloramphenicol

Ceftazidime

Cefazolin

Cefotaxime

Irvine, 1992 [35]

1

0/1

0/1

 

0/1

      

1/1

  

Pathengay, 2005 [20]

1

0/1

0/1

 

1/1

     

0/1

1/1

  

Eser 2006 [11]

2

0/2

0/2

0/2

2/2

 

2/2

    

2/2

  

Sachdeva, 2011 [26]

14

6/14

7/14

 

11/14

     

9/14

11/14

1/14

 

Lalitha, 201412

13

0/13

0/13

0/13

0/13

0/13

0/13

0/13

0/13

 

0/13

0/13

 

13/13

Saffra, 2014 [27]

1

 

0/1

  

1/1

     

1/1

0/1

0/1

Deka, 2018 [6]

3

       

0/2

  

2/2*

  

Okonkwo, 2018 [17]

2

0/2

0/2

 

0/2

      

2/2**

  

Lind, 2021 [14]

6

6/6

0/6

0/6

6/6

      

6/6

 

0/6

Deb, 2021 [7]

5

          

5/5**

  

Current study

3

1/1

1/1

1/1

1/1

1/1

   

2/2

 

3/3

  

Total

51

13/40

8/41

1/22

21/40

2/15

2/13

0/13

0/13

2/2

9/28

34/50

1/15

13/20

Percentage

 

0.33

0.20

0.05

0.53

0.13

0.15

0

0

1

0.32

0.68

0.07

0.65

 

Cephalosporins

Extended Spectrum Pencillins & Carbopenams

   

Study

Cefuroxime

Cefixime

Ceftriaxone

Cefoxitin

Cefepime

Ampicillin

Pipercillin-Tazobactam

Avibactam-ceftazidim

Ceftolozane-tazobactam

Imipenem

Meropenem

Vancomycin

Trimethoprim-sulfametoxazole

Nitrofurantoin

Irvine, 1992 [35]

           

0/1

  

Pathengay, 2005 [19[]

           

0/1

  

Eser 2006 [11]

  

0/2

0/2

          

Sachdeva, 2011 [26]

           

0/14

  

Lalitha, 2014 [12]

0/13

     

13/13

       

Saffra, 2014 [27]

     

0/1

       

0/1

Deka, 2018 [6]

 

0/2

            

Okonkwo, 2018 [17]

            

2/2**

 

Lind, 2021 [14]

0/6

     

6/6

0/6

0/6

0/6

0/6

 

0/6

 

Deb, 2021 [7]

          

5/5**

 

5/5**

 

Current study

    

1/1

 

1/1

   

3/3

 

1/3

 

Total

0/19

0/2

0/2

0/2

1/1

0/1

20/20

0/6

0/6

0/6

8/14

0/16

8/16

0/1

Percentage

0

0

0

0

1

0

1

0

0

0

0.57

0

0.5

0

  1. Antibiotic susceptibilities as reported by previous published reports. *Deka et al. reported intermediate susceptibility to ceftazidime among both isolates. **Okonkwo et al. 2019 and Deb et al. 2021, only specified susceptible antibiotics though more agents were tested which were not reported
Back to article page